Dossier
vaccine deals
Coverage of vaccine deals in the Nexus archive.
- Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals
Eli Lilly's stock increased as the company plans nearly $4 billion in vaccine deals to expand into infectious disease research and development.